Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms

AUTOR(ES)

Goldin, Lynn R

FONTE

BioMed Central

RESUMO

Myeloproliferative neoplasms (MPNs) are a group of closely related stem-cell-derived clonal proliferative diseases. Most cases are sporadic but first-degree relatives of MPN patients have a five- to seven-fold increased risk for developing an MPN. The tumors of most patients carry a mutation in the Janus kinase 2 gene (JAK2V617F). Recently, three groups have described a strong association of JAK2 germline polymorphisms with MPN in patients positive for JAK2V617F. The somatic mutation occurs primarily on one particular germline JAK2 haplotype, which may account for as much as 50% of the risk to first-degree relatives. This finding provides new directions for unraveling the pathogenesis of MPN.

Documentos Relacionados

• The JAK2 gene as a protagonist in chronic myeloproliferative neoplasms
• Evaluation of the association between the JAK2 46/1 haplotype and chronic myeloproliferative neoplasms in a Brazilian population
• The JAK2 V617F mutation in Philadelphia‐negative chronic myeloproliferative disorders
• Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F
• Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview